Rhythm Pharmaceuticals In... (RYTM)
NASDAQ: RYTM
· Real-Time Price · USD
61.84
2.25 (3.78%)
At close: May 29, 2025, 3:59 PM
63.61
2.86%
After-hours: May 29, 2025, 07:33 PM EDT
3.78% (1D)
| Bid | 61.93 |
| Market Cap | 3.93B |
| Revenue (ttm) | 136.86M |
| Net Income (ttm) | -170.02M |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -22.09 |
| Forward PE | -41.62 |
| Analyst | Strong Buy |
| Ask | 64 |
| Volume | 468,721 |
| Avg. Volume (20D) | 723,547 |
| Open | 60.95 |
| Previous Close | 59.59 |
| Day's Range | 60.15 - 63.24 |
| 52-Week Range | 35.35 - 68.58 |
| Beta | 2.37 |
About RYTM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RYTM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RYTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+5.04%
Rhythm Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
1 month ago
+17.06%
Rhythm Pharmaceuticals shares are trading higher after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint.
1 month ago · seekingalpha.com
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity DisorderRhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...
